These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 18085684)

  • 1. Effect of race on vincristine-associated neurotoxicity in pediatric acute lymphoblastic leukemia patients.
    Renbarger JL; McCammack KC; Rouse CE; Hall SD
    Pediatr Blood Cancer; 2008 Apr; 50(4):769-71. PubMed ID: 18085684
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased risk of vincristine neurotoxicity associated with low CYP3A5 expression genotype in children with acute lymphoblastic leukemia.
    Egbelakin A; Ferguson MJ; MacGill EA; Lehmann AS; Topletz AR; Quinney SK; Li L; McCammack KC; Hall SD; Renbarger JL
    Pediatr Blood Cancer; 2011 Mar; 56(3):361-7. PubMed ID: 21225912
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of CYP3A5 Expression and Vincristine Neurotoxicity in Pediatric Malignancies in Turkish Population.
    Kayilioğlu H; Kocak U; Kan Karaer D; Percin EF; Sal E; Tekkesin F; Isik M; Oner N; Belen FB; Yilmaz Keskin E; Okur A; Albayrak M; Kaya Z; Pinarli FG; Yenicesu I; Karadeniz C; Oguz A; Gursel T
    J Pediatr Hematol Oncol; 2017 Aug; 39(6):458-462. PubMed ID: 28697165
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of race on the CYP3A-mediated metabolism of vincristine in pediatric patients with acute lymphoblastic leukemia.
    Sims RP
    J Oncol Pharm Pract; 2016 Feb; 22(1):76-81. PubMed ID: 25305360
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Severe Vincristine-related Neurotoxicity in 5 Patients With Pediatric Acute Lymphoblastic Leukemia Requiring Discontinuation of Vincristine: A Description of Long-term Outcome.
    Egan-Sherry D; Bhuta R; Cole PD; Gennarini LM; Kahn JM; Sulis ML; DeNardo BD; Welch JJG
    J Pediatr Hematol Oncol; 2021 Oct; 43(7):e997-e999. PubMed ID: 34001785
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Variants in vincristine pharmacodynamic genes involved in neurotoxicity at induction phase in the therapy of pediatric acute lymphoblastic leukemia.
    Martin-Guerrero I; Gutierrez-Camino A; Echebarria-Barona A; Astigarraga I; Garcia de Andoin N; Navajas A; Garcia-Orad A
    Pharmacogenomics J; 2019 Dec; 19(6):564-569. PubMed ID: 30723315
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of plasma and intracellular exposure and CYP3A4, CYP3A5, and ABCB1 genetic polymorphisms on vincristine-induced neurotoxicity.
    Guilhaumou R; Solas C; Bourgarel-Rey V; Quaranta S; Rome A; Simon N; Lacarelle B; Andre N
    Cancer Chemother Pharmacol; 2011 Dec; 68(6):1633-8. PubMed ID: 21968951
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vincristine pharmacokinetics pathway and neurotoxicity during early phases of treatment in pediatric acute lymphoblastic leukemia.
    Lopez-Lopez E; Gutierrez-Camino A; Astigarraga I; Navajas A; Echebarria-Barona A; Garcia-Miguel P; Garcia de Andoin N; Lobo C; Guerra-Merino I; Martin-Guerrero I; Garcia-Orad A
    Pharmacogenomics; 2016 May; 17(7):731-41. PubMed ID: 27180762
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incidence of vincristine induced neurotoxicity in children with acute lymphoblastic leukemia and its correlation with nutritional deficiencies.
    Dudeja S; Gupta S; Sharma S; Jain A; Sharma S; Jain P; Aneja S; Chandra J
    Pediatr Hematol Oncol; 2019 Sep; 36(6):344-351. PubMed ID: 31514565
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vincristine pharmacodynamics and pharmacogenetics in children with cancer: a limited-sampling, population modelling approach.
    Moore AS; Norris R; Price G; Nguyen T; Ni M; George R; van Breda K; Duley J; Charles B; Pinkerton R
    J Paediatr Child Health; 2011 Dec; 47(12):875-82. PubMed ID: 21658147
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potentiation of vincristine toxicity by itraconazole in children with lymphoid malignancies.
    Kamaluddin M; McNally P; Breatnach F; O'Marcaigh A; Webb D; O'Dell E; Scanlon P; Butler K; O'Meara A
    Acta Paediatr; 2001 Oct; 90(10):1204-7. PubMed ID: 11697438
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of an inherited genetic variant with vincristine-related peripheral neuropathy in children with acute lymphoblastic leukemia.
    Diouf B; Crews KR; Lew G; Pei D; Cheng C; Bao J; Zheng JJ; Yang W; Fan Y; Wheeler HE; Wing C; Delaney SM; Komatsu M; Paugh SW; McCorkle JR; Lu X; Winick NJ; Carroll WL; Loh ML; Hunger SP; Devidas M; Pui CH; Dolan ME; Relling MV; Evans WE
    JAMA; 2015 Feb; 313(8):815-23. PubMed ID: 25710658
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vincristine-induced peripheral neuropathy in survivors of childhood acute lymphoblastic leukaemia.
    Tay CG; Lee VWM; Ong LC; Goh KJ; Ariffin H; Fong CY
    Pediatr Blood Cancer; 2017 Aug; 64(8):. PubMed ID: 28139029
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Severe life threatening neurotoxicity in a child with acute lymphoblastic leukemia receiving posaconazole and vincristine.
    Jain S; Kapoor G
    Pediatr Blood Cancer; 2010 May; 54(5):783. PubMed ID: 20205256
    [No Abstract]   [Full Text] [Related]  

  • 15. Glutamic acid not beneficial for the prevention of vincristine neurotoxicity in children with cancer.
    Bradfield SM; Sandler E; Geller T; Tamura RN; Krischer JP
    Pediatr Blood Cancer; 2015 Jun; 62(6):1004-10. PubMed ID: 25545757
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A trial to assess the efficacy of glutamic acid in prevention of vincristine-induced neurotoxicity in pediatric malignancies: a pilot study.
    Mokhtar GM; Shaaban SY; Elbarbary NS; Fayed WA
    J Pediatr Hematol Oncol; 2010 Nov; 32(8):594-600. PubMed ID: 20921909
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fluoroquinolone prophylaxis does not increase risk of neuropathy in children with acute lymphoblastic leukemia.
    Karol SE; Sun Y; Tang L; Pui CH; Ferrolino J; Allison KJ; Cross SJ; Evans WE; Crews KR; Jeha S; Wolf J
    Cancer Med; 2020 Sep; 9(18):6550-6555. PubMed ID: 32710497
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Posaconazole-increased vincristine neurotoxicity in a child: a case report.
    Eiden C; Palenzuela G; Hillaire-Buys D; Margueritte G; Cociglio M; Hansel-Esteller S; Peyriere H
    J Pediatr Hematol Oncol; 2009 Apr; 31(4):292-5. PubMed ID: 19346885
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potentiation of vincristine toxicity with concomitant fluconazole prophylaxis in children with acute lymphoblastic leukemia.
    Teusink AC; Ragucci D; Shatat IF; Kalpatthi R
    Pediatr Hematol Oncol; 2012 Feb; 29(1):62-7. PubMed ID: 22304011
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vincristine neurotoxicity in the presence of hereditary neuropathy.
    Trobaugh-Lotrario AD; Smith AA; Odom LF
    Med Pediatr Oncol; 2003 Jan; 40(1):39-43. PubMed ID: 12426685
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.